Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8538844 | 1.00 | DRD2 (0.65) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL4536932 | 1.00 | DRD2 (0.65) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL1626963 | 1.00 | DRD2 (0.65) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL28148490 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| Ammonia Solution, Strong SCHEMBL27880976 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL319782 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL1711121 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL28845061 | 0.98 | DRD2 (0.63) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL27453341 | 0.90 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL19866138 | 0.89 | DRD2 (0.53) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1081 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140874-A1 | IRON COMPLEX, PREPARATION METHOD THEREFOR, COMPOSITION, SLURRY, AND APPLICATION | 华为技术有限公司 | 2024-07-04 | — | — | WO | claimed |
| CN-115304607-A | Process for preparing pyrazolopyrimidine derivatives | 华南农业大学 | 2022-11-08 | — | — | CN | claimed |
| CN-109742250-B | Organic light emitting diode and display device | 云谷（固安）科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | claimed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | claimed |
| EP-3802492-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | Oxford University Innovation Limited (GB) | 2021-04-14 | — | — | EP | claimed |
| CN-111138307-A | Aryl halide and synthesis method and application thereof | 华东师范大学 | 2020-05-12 | — | — | CN | claimed |
| WO-2019234405-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-12-12 | — | — | WO | claimed |
| CN-105705147-B | Novel oxazolidone antimicrobial compound | 李药业有限公司 | 2019-06-28 | — | — | CN | claimed |
| CN-109776324-A | Homoallyltrifluoromethyl compound and preparation method thereof | 南京工业大学 | 2019-05-21 | — | — | CN | claimed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| CN-1154699-A | (Azetidin-1-ylalkyl) lactams as tachykinin antagonists | PFIZER LTD (IE) | 1997-07-16 | — | — | CN | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| EP-0080940-B1 | DERIVATIVES OF 2-PHENYL-MORPHOLINE AND MEDICAL COMPOSITIONS | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1986-02-19 | — | — | EP | claimed |
| EP-0139590-A2 | 4-Ethyl-2-hydroxy-3-methyl-2-phenylmorpholine and its addition salts | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-05-02 | — | — | EP | claimed |
| EP-0027695-B1 | MORPHOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | JOHN WYETH & BROTHER LIMITED (GB) | 1983-10-12 | — | — | EP | claimed |
| EP-0080940-A2 | Derivatives of 2-phenyl-morpholine and medical compositions | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1983-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | DRD2 4780/4885DRD3 4694/4885HTR1A 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.